US Broker Ratings

DexCom, Inc. (DXCM) Stock Analysis: A Compelling 22% Upside Amidst Growing Healthcare Demand

Investors in the healthcare sector might find DexCom, Inc. (DXCM) an intriguing prospect, especially considering its pivotal role in the medical devices industry. With a market capitalization of $27.31 billion,..

Novartis AG (NVS) Stock Analysis: Navigating Growth with a 2.93% Dividend Yield in the Healthcare Sector

For individual investors seeking opportunities in the healthcare sector, Novartis AG (NYSE: NVS) presents an intriguing case. As a Swiss pharmaceutical giant, Novartis commands a market capitalization of $315.28 billion,..

Danaher Corporation (DHR) Stock Analysis: Exploring a 24.62% Potential Upside and Strong Buy Ratings

Danaher Corporation (NYSE: DHR) stands as a formidable entity within the Healthcare sector, specifically in the Diagnostics & Research industry. With a market capitalization of $150.27 billion, Danaher is a..

HCA Healthcare, Inc. (HCA) Stock Analysis: Evaluating Growth Potential and Market Position

Investors seeking a robust presence in the healthcare sector should consider HCA Healthcare, Inc. (NYSE: HCA), a titan in the medical care facilities industry with a considerable market cap of..

Medtronic plc (MDT) Stock Analysis: Riding the Upside Wave with 12.57% Potential Growth

Medtronic plc (MDT), headquartered in Galway, Ireland, stands as a formidable player in the healthcare sector, specifically within the medical devices industry. With a market capitalization of $127.61 billion, Medtronic..

Oric Pharmaceuticals, Inc. (ORIC) Stock Analysis: Biotech Innovator with Over 105% Potential Upside

Oric Pharmaceuticals, Inc. (NASDAQ: ORIC), a burgeoning player in the biotechnology sector, is capturing the attention of investors with its promising pipeline of cancer therapies and a remarkable potential upside..

MBX Biosciences, Inc. (MBX) Stock Analysis: A Biotech with a 60.79% Potential Upside

MBX Biosciences, Inc. (MBX) is making waves in the biotechnology sector with its focus on precision peptide therapies aimed at treating endocrine and metabolic disorders. With a market cap of..

Septerna, Inc. (SEPN) Stock Analysis: Biotechnology Pioneer with 31.43% Upside Potential

Septerna, Inc. (SEPN), a burgeoning name in the biotechnology sector, has captured investor attention with its remarkable revenue growth and potential upside. As a clinical-stage biotech company, Septerna is pioneering..

Abivax SA (ABVX) Stock Analysis: A 22.77% Potential Upside and Strong Buy Consensus

Abivax SA (ABVX), a French biotechnology powerhouse, is drawing significant investor attention with its promising potential upside of 22.77% as indicated by analyst targets. Operating at the cutting edge of..

Fortrea Holdings Inc. (FTRE) Stock Analysis: Biotechnology Player with a 60% Upside Potential

As a relatively new entrant in the healthcare sector, Fortrea Holdings Inc. (NASDAQ: FTRE) is making waves in the biotechnology industry. Incorporated in 2023 and headquartered in Durham, North Carolina,..

PureTech Health plc (PRTC) Stock Analysis: Unveiling a 542.7% Revenue Growth Potential

PureTech Health plc (PRTC), a biotechnology firm based in Boston, Massachusetts, is quietly making waves in the healthcare sector. With a focus on developing and commercializing innovative biotech and pharmaceutical..

AtaiBeckley Inc. (ATAI) Stock Analysis: Unveiling a 247.89% Potential Upside in Revolutionary Mental Health Treatments

For investors with an eye on the healthcare sector, AtaiBeckley Inc. (NASDAQ: ATAI) offers a compelling case of innovation in mental health treatment, coupled with a striking potential upside of..

Neuropace, Inc. (NPCE) Stock Analysis: A 34% Potential Upside Sparks Investor Interest

Neuropace, Inc. (NASDAQ: NPCE), a pioneering player in the healthcare sector, is drawing significant attention from investors. With its focus on medical devices, specifically targeting drug-resistant focal epilepsy through its..

Humacyte, Inc. (HUMA)

⚠️ No article content returned.

..

Xencor, Inc. (XNCR) Investor Outlook: A Biotech Stock with a 148% Potential Upside

Xencor, Inc. (NASDAQ: XNCR) is capturing the attention of investors in the healthcare sector, particularly those interested in biotechnology. The company, based in Pasadena, California, is a clinical-stage biopharmaceutical entity..

Rapport Therapeutics, Inc. (RAPP) Stock Analysis: A Deep Dive into Its 83% Potential Upside

Rapport Therapeutics, Inc. (NASDAQ: RAPP) is generating significant buzz in the biotechnology sector with its promising pipeline of treatments for central nervous system (CNS) disorders. As a clinical-stage biopharmaceutical company,..

Autolus Therapeutics plc (AUTL) Stock Analysis: Exploring a 575% Potential Upside in Groundbreaking T Cell Therapies

Autolus Therapeutics plc (NASDAQ: AUTL), a prominent player in the biotechnology sector, is capturing investor attention with its innovative T cell therapies aimed at treating cancer and autoimmune diseases. Headquartered..

AnaptysBio, Inc. (ANAB) Stock Analysis: Unpacking the 23.71% Potential Upside for Investors

AnaptysBio, Inc. (NASDAQ: ANAB), a clinical-stage biotechnology company, has recently captured investor attention due to its promising potential upside of 23.71%. With a market capitalization of $1.54 billion, AnaptysBio operates..

Sonida Senior Living, Inc. (SNDA): Navigating Healthcare Challenges with a 25.9% Revenue Surge

Sonida Senior Living, Inc. (NYSE: SNDA), a prominent player in the healthcare sector, specializes in providing senior housing and a broad array of care services across the United States. With..

Standard BioTools Inc. (LAB) Stock Analysis: Unpacking a 39.64% Potential Upside in the Healthcare Sector

Standard BioTools Inc. (NASDAQ: LAB), a prominent player in the medical devices sector, presents an intriguing opportunity for investors with its considerable potential upside of 39.64%. Known for its innovative..

Search

Funds

US Broker Ratings

Search

Funds

US Broker Ratings

FTSE 100

Funds